The Otago team were instrumental in establishing our organisation within the United Kingdom and key European territories.  We decided to utilize Otago as our vehicle for entry into these important strategic markets as they offered a model which had a significantly low-cost base but one which offered fast penetration, quicker return on our initial investment and importantly sales for our organisation. This was developed further when we worked on our lead Orphan Drug for Head and Neck Carcinomas.  Otago’s expertise and knowledge in this area was invaluable as we established a Pan-European and Middle Eastern platform to ensure the product was made accessible to key centres of excellence, physicians and patients.

Dr Claus Moller, Chairman , Azanta Limited
Dr Claus Moller, Chairman


Our experience working with Otago has been always more than satisfactory: good business understanding, honesty, and three key aspects for us: “quickness, simplicity and clear”. We feel very comfortable and proud to have the opportunity to collaborate with Otago in the past, in the present and hopefully also in the near future
Dr Sergi Trilla, Trifermed S.F.
Dr Sergi Trilla


“Saneev Pooni was one of the first employees as Head of Operations in Nycomed UK. He had a clear mission to work integrally with the Managing Director to build a strong organisation which ensured a successful launch of the company.

Sanjeev insight and knowledge of this market combined with his contact base was pivotal to us introducing products very fast and successful. Our key cardiology product achieved sales of 1 Million Euro within 12 Months of launch which was part of Nycomed’s Pan-European launch”.

Timo Tivola


“Sanjeev was pivotal establishing Bayer’s Generic arm (Ethical Generic Limited) within the United Kingdom in 1996. His knowledge customer base and strategic involvement was crucial to the rapid uptake of key products and ensuring that the organisation achieved significant revenue from launch.

We launched Ethical Generics in February 1996, and by December has achieved group turnover of 1.1 Million Euro.”

Roger Cuff


Otago Healthcare have really impressed us with the work they carried out as part of the market evaluation for our core products. Their professionalism and expertise really consolidated our strategic plans for the UK & Eire as well as other key emerging markets.
Dr Vesa Kleimola, CEO & President, Biofile Diagnostics
Dr Vesa Kleimola, CEO & President